Zepbound and Alcohol: Label Warnings and Drinking Evidence
The Zepbound and Mounjaro Drug Interactions sections cover insulin, sulfonylureas, and oral medications. A study of more than 120 million US health records linked tirzepatide to about half the rate of new alcohol use disorder diagnoses (HR 0.47), and a 42-person randomized trial is underway.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Zepbound and Mounjaro are brand names for the same active drug, tirzepatide [1][2]. The Drug Interactions sections of both prescribing information documents cover two topics: use with insulin or insulin secretagogues such as sulfonylureas, and effects on oral medications [1][2]. The safety warnings that matter most to anyone who drinks are the ones the labels do carry — volume depletion and kidney injury, low blood sugar when tirzepatide is combined with insulin or a sulfonylurea, and pancreatitis [1][2][7].
On the question of whether tirzepatide cuts drinking: a 2025 study using electronic health records from a US network of more than 120 million patients found that adults with type 2 diabetes who started tirzepatide had about half the rate of new alcohol use disorder diagnoses over 18 months compared with similar patients taking DPP-4 inhibitors, with a hazard ratio of 0.47 (95% CI 0.29-0.75) [3]. That is an association, not proof of cause, and a 42-person randomized trial of tirzepatide in adults with alcohol use disorder began in October 2025 [4].
What is the difference between Zepbound and Mounjaro?
Both products are tirzepatide injections [1][2]. Zepbound is indicated, along with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction in adults with obesity, or overweight plus at least one weight-related condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity [1]. Mounjaro is indicated to improve glycemic control in adults and children 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events [2].
The Zepbound label states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended [1]. Because both brands contain the same active drug, the alcohol-related information on this page applies to both.
Is alcohol listed as a drug interaction for tirzepatide?
Section 7 of the Zepbound label contains two subsections: 7.1, concomitant use with insulin or an insulin secretagogue (for example, a sulfonylurea), and 7.2, oral medications [1]. The Mounjaro label carries the same two subsections [2].
Subsection 7.2 explains that Zepbound delays gastric emptying and can affect the absorption of oral medications taken at the same time. It advises monitoring patients on oral drugs that depend on threshold concentrations for their effect, or that have a narrow therapeutic index, such as warfarin [1]. The same guidance extends to oral hormonal contraceptives: the label advises users to switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation [1].
Why dehydration and kidney injury are on the warning list
The Zepbound label carries a warning for acute kidney injury due to volume depletion [1]. Postmarketing reports include cases that required hemodialysis, and the label states that most reported cases occurred in patients who had gastrointestinal reactions leading to dehydration — nausea, vomiting, or diarrhea [1]. The label advises monitoring renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [1].
Those gastrointestinal reactions are common. In a pool of the two Zepbound weight-reduction trials (Studies 1 and 2), nausea occurred in 25% to 29% of Zepbound patients versus 8% on placebo, diarrhea in 19% to 23% versus 8%, and vomiting in 8% to 13% versus 2% [1]. Acute kidney injury itself was reported in 0.5% of Zepbound patients versus 0.2% on placebo in the same pooled trials [1].
What is the low blood sugar risk on tirzepatide, and which combinations raise it?
The Zepbound label states that Zepbound lowers blood glucose and can cause hypoglycemia, and both labels state that the risk rises when tirzepatide is combined with insulin or an insulin secretagogue such as a sulfonylurea [1][2]. Here are the rates from the clinical trials, all for blood glucose below 54 mg/dL:
| Trial and population | Tirzepatide group | Comparison group |
|---|---|---|
| Zepbound Study 2 — type 2 diabetes, BMI 27+ | 4.2% | 1.3% on placebo [1] |
| Zepbound Study 2 — patients also on a sulfonylurea | 10.3% | 2.1% for Zepbound patients not on a sulfonylurea [1] |
| Zepbound Study 1 — obesity, no diabetes | 0.3% | none on placebo; hypoglycemia was not systematically captured [1] |
| Mounjaro monotherapy, 40 weeks — type 2 diabetes | 0% at all doses | 1% on placebo [2] |
| Mounjaro added to basal insulin, 40 weeks | 14% to 19% | 13% on placebo; severe episodes 1% to 2% versus 0 [2] |
The Zepbound label states that the risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea, and that patients should be informed of the signs and symptoms of low blood sugar [1].
What are the pancreatitis and gallbladder warnings?
Both labels warn that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or tirzepatide, and to discontinue the drug if pancreatitis is suspected [1][2]. Symptoms include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1].
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) strengthened its warnings on January 29, 2026. Between 2007 and October 2025, the agency received 1,296 Yellow Card reports of pancreatitis associated with GLP-1 or GLP-1/GIP receptor agonists, of which 19 were fatal and 24 were reported as necrotizing pancreatitis [7]. The MHRA advises using these drugs with caution in patients with a history of pancreatitis, not restarting treatment if pancreatitis is confirmed, and notes that early symptoms may be mistaken for common gastrointestinal side effects of these drugs [7].
The Zepbound trials also showed gallbladder events: cholelithiasis in 1.1% of Zepbound patients versus 1% on placebo, cholecystitis in 0.7% versus 0.2%, and cholecystectomy in 0.2% versus none [1].
Does alcohol hit differently on a GLP-1 drug?
Zepbound delays gastric emptying, and the label states the delay is largest after the first dose and diminishes over time [1]. That mechanism is why researchers have asked whether alcohol, which enters the blood in the upper intestine, moves more slowly into the blood on these drugs [6].
A 2025 pilot study in Scientific Reports tested this directly. Twenty participants with obesity were split 1:1 into a group taking a GLP-1 receptor agonist and a control group, and both consumed a challenge dose of alcohol [6]. The GLP-1 group showed a delayed rise in breath alcohol of up to 20 minutes and a delayed onset of subjective effects, a difference the researchers said was not explained by nausea [6]. By 1 hour after drinking, breath alcohol in the GLP-1 group was no different from controls [6].
The limits matter: most participants were taking semaglutide, with only 2 on tirzepatide and 2 on liraglutide, the study was not randomized, and the sample was small [6]. This pilot has not measured breath alcohol in a group of tirzepatide users beyond those two participants.
Does tirzepatide reduce alcohol cravings or drinking?
The largest piece of evidence is the 2025 target trial emulation described at the top of this page. It used a US electronic health record network covering more than 120 million patients, followed adults with type 2 diabetes and no prior alcohol use disorder diagnosis for 18 months, and compared each GLP-1 drug with DPP-4 inhibitors using propensity-score matching [3]. The matched tirzepatide cohort had 7,165 patients and the semaglutide cohort 20,198 [3].
Tirzepatide and semaglutide were both associated with a lower incidence of alcohol use disorder — hazard ratios of 0.47 (95% CI 0.29-0.75) and 0.68 (95% CI 0.52-0.89), respectively — while liraglutide and dulaglutide showed no significant difference versus DPP-4 inhibitors [3]. In a head-to-head analysis, tirzepatide showed a significant reduction compared with liraglutide (HR 0.47, 95% CI 0.24-0.92) [3]. The study measured the outcome as a first ICD-10 diagnosis code for alcohol use disorder (F10) in medical records, and the authors concluded that randomized controlled evidence is needed for this potential use [3].
Other human evidence, summarized in the Scientific Reports paper, points in the same direction but varies in strength [6]:
- A 2023 survey study found that people taking semaglutide or tirzepatide reported reduced drinking and binge episodes, and reduced sedative and stimulative effects of alcohol [6].
- A randomized trial of exenatide found fewer heavy drinking days, but only in a subgroup with BMI over 30 [6].
- A randomized trial of semaglutide published in JAMA Psychiatry in 2025 found reduced alcohol intake in a lab challenge, fewer drinks per drinking day, and reduced craving [6].
- A secondary analysis of a dulaglutide smoking-cessation trial found alcohol intake fell by 36% [6].
Is tirzepatide approved to treat alcohol use disorder?
Zepbound’s labeled indications are weight reduction and long-term maintenance in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity [1]. Mounjaro’s labeled indications are glycemic control in type 2 diabetes and reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk [2]. Research on tirzepatide for alcohol use disorder is still at the clinical trial stage [4].
When will the tirzepatide alcohol trial results be out?
A Phase 2 trial (NCT06994338) at the University of Southern California, funded by an NIH grant, is comparing tirzepatide injections with placebo in adults who have both alcohol use disorder and overweight or obesity [4]. Estimated enrollment is 42 participants, with tirzepatide doses of 2.5 mg and 5 mg; the primary outcome is heavy drinking days during treatment weeks 5 through 8 [4].
The study started on October 6, 2025, with an estimated primary completion date of August 31, 2026 [4]. The registry record, last updated in October 2025, lists the trial as recruiting with no results posted [4].
Sources
- National Library of Medicine DailyMed. ZEPBOUND (tirzepatide) injection, solution. Drug label.
- National Library of Medicine DailyMed. MOUNJARO (tirzepatide) injection, solution. Drug label.
- PubMed. Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
- ClinicalTrials.gov. Tirzepatide for Alcohol Use Disorder. Study NCT06994338.
- eBioMedicine (The Lancet). Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
- Scientific Reports (Nature). A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity.
- GOV.UK. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. Drug safety update.
- New England Journal of Medicine. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Frequently asked questions
Can you drink alcohol on Zepbound or Mounjaro?
The Drug Interactions sections of both labels address insulin, insulin secretagogues, and oral medications. The warnings most relevant alongside alcohol are volume depletion and kidney injury, low blood sugar when tirzepatide is combined with insulin or a sulfonylurea, and pancreatitis.
Is alcohol listed as a drug interaction for tirzepatide?
Section 7 of both the Zepbound and Mounjaro labels has two subsections: 7.1 covers concomitant use with insulin or an insulin secretagogue such as a sulfonylurea, and 7.2 covers oral medications, including delayed-absorption guidance for narrow-therapeutic-index drugs like warfarin and for oral contraceptives.
Why might alcohol feel stronger or slower on tirzepatide?
Zepbound delays gastric emptying, with the delay largest after the first dose and diminishing over time. In a 20-person pilot, the GLP-1 group had a delayed rise in breath alcohol of up to 20 minutes and delayed subjective effects, with no difference from controls by 1 hour. Only 2 participants were on tirzepatide.
Does tirzepatide reduce alcohol cravings?
A 2023 survey study of semaglutide and tirzepatide users reported reduced drinking and binge episodes. In records covering more than 120 million patients, tirzepatide was associated with about half the rate of new alcohol use disorder diagnoses versus DPP-4 inhibitors (HR 0.47). A randomized trial in alcohol use disorder is recruiting.
What does the pancreatitis warning on Zepbound say, and which symptoms does it list?
The Zepbound and Mounjaro labels warn of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, with symptoms of persistent or severe abdominal pain that may radiate to the back, with or without nausea or vomiting. The MHRA reported 1,296 UK pancreatitis reports with these drug classes from 2007 to October 2025, of which 19 were fatal.
What is the hypoglycemia risk when tirzepatide is combined with insulin or a sulfonylurea?
The Zepbound label states that Zepbound lowers blood glucose and can cause hypoglycemia, and that combining it with insulin or a sulfonylurea raises the risk. In a Zepbound trial of adults with type 2 diabetes, glucose below 54 mg/dL occurred in 10.3% of patients also taking a sulfonylurea versus 2.1% of those not taking one. With Mounjaro added to basal insulin, rates were 14% to 19% versus 13% on placebo.
Is tirzepatide approved to treat alcohol use disorder?
Zepbound's labeled indications are weight reduction and obstructive sleep apnea in adults with obesity; Mounjaro's are glycemic control in type 2 diabetes and cardiovascular risk reduction. A Phase 2 trial of tirzepatide for alcohol use disorder in adults with overweight or obesity is currently recruiting.
When will the tirzepatide alcohol trial results be out?
The trial (NCT06994338) started on October 6, 2025 with an estimated primary completion date of August 31, 2026, measuring heavy drinking days in treatment weeks 5 through 8. The registry record, last updated in October 2025, lists the study as recruiting with no results posted.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.